PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.31%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-49.44%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
3.87%
Other expenses change of 3.87% while RVPH maintains costs. Bruce Berkowitz would investigate efficiency.
-37.34%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-37.34%
Both companies reducing total costs. Martin Whitman would check industry trends.
-62.14%
Both companies reducing interest expense. Martin Whitman would check industry trends.
3.87%
D&A change of 3.87% while RVPH maintains D&A. Bruce Berkowitz would investigate efficiency.
47.24%
EBITDA growth exceeding 1.5x RVPH's 5.85%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
37.34%
Operating income growth exceeding 1.5x RVPH's 7.11%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
1271.24%
Other expenses growth while RVPH reduces costs. John Neff would investigate differences.
47.13%
Pre-tax income growth exceeding 1.5x RVPH's 5.94%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-62.14%
Tax expense reduction while RVPH shows 52.58% growth. Joel Greenblatt would examine advantage.
47.13%
Net income growth exceeding 1.5x RVPH's 5.90%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
50.90%
EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
52.86%
Diluted EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
7.67%
Share count reduction below 50% of RVPH's 2.47%. Michael Burry would check for concerns.
12.32%
Diluted share reduction below 50% of RVPH's 2.47%. Michael Burry would check for concerns.